Article
Oncology
Yukiko Kiniwa, Kenta Nakamura, Asuka Mikoshiba, Atsuko Ashida, Yasuyuki Akiyama, Atsushi Morimoto, Ryuhei Okuyama
Summary: CTCs are present even in early-stage melanoma and the number of CTCs may reflect patients' responses to BRAF/MEK inhibitor treatment. Furthermore, genetic heterogeneity of BRAF may contribute to resistance to BRAF/MEK inhibitors.
Review
Oncology
Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, Claudio Tabolacci
Summary: Cutaneous melanoma, the most aggressive form of skin cancer, is driven by the accumulation of genetic alterations, including BRAF mutations. Targeted therapies against these mutations have revolutionized the treatment of melanoma patients, but resistance remains a challenge. This review summarizes recent findings on the impact of BRAF mutations on melanoma development, with a focus on inflammation, as well as the mechanisms of resistance to BRAF inhibitors and circulating tumor biomarkers.
Article
Oncology
Sofie H. Tolmeijer, Rutger H. T. Koornstra, Jan Willem B. de Groot, Maartje J. Geerlings, Dirk H. van Rens, Marye J. Boers-Sonderen, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra
Summary: For patients with metastatic melanoma, rapid BRAF mutation assessment is crucial, with ctDNA proving to be a reliable alternative to tissue-based testing. Monitoring disease progression and treatment response through ctDNA levels is superior to other blood-based biomarkers, showing promise for diagnostic and monitoring purposes.
Article
Ophthalmology
Jasmine H. Francis, Christopher A. Barker, A. Rose Brannon, Julia Canestraro, Melissa Robbins, Christina E. Swartzwelder, Sara Levine, Crystal Law, Michael F. Berger, Alexander Shoushtari, David H. Abramson
Summary: This study aims to investigate the presence of plasma circulating tumor DNA (ctDNA) in patients with uveal melanoma during and after primary tumor treatment. The study found that ctDNA was significantly more detectable at 48 to 72 hours after plaque brachytherapy compared with less than 48 hours, and ctDNA can also be detected during enucleation. Relative increases in ctDNA levels may herald the development of clinically apparent metastases.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2022)
Article
Oncology
Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine M. M. Bui, Charuta C. C. Palsuledesai, Meenakshi Malhotra, Perry Olshan, Joseph Markowitz, Nikhil I. I. Khushalani, Ahmad A. A. Tarhini, Jane L. L. Messina, Alexey Aleshin
Summary: In this study, a personalized and tumor-informed ctDNA assay was used to analyze plasma samples from 69 patients with advanced melanoma. The results showed that ctDNA levels were correlated with survival and disease progression in these patients, suggesting that it could be a reliable biomarker for predicting treatment response and disease recurrence.
Review
Oncology
Helena J. Janse van Rensburg, Pavlina Spiliopoulou, Lillian L. Siu
Summary: Circulating biomarkers play a valuable role in evaluating disease states in solid malignancies, and their use in monitoring treatment response is diverse, including disease burden markers, tumor markers, circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays. This review summarizes the discovery and application of these circulating biomarkers in influencing treatment decisions, as well as the barriers to their application.
Article
Oncology
Tapas Ranjan Behera, Jung Min Song, Jennifer Ko, Donald Eicher, Joshua Arbesman, Brian Gastman, Daniel H. Farkas, Pauline Funchain
Summary: In the treatment of metastatic melanoma, a plasma-based, near point-of-care detection system can support treatment decisions in emergency situations, avoiding invasive and time-consuming biopsies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Marina A. Emelyanova, Ekaterina N. Telysheva, Kristina Orlova, Oxana O. Ryabaya, Galina P. Snigiryova, Ivan S. Abramov, Vladimir M. Mikhailovich
Summary: This study developed a novel microarray technology for simultaneous detection of six BRAF V600 mutations in ctDNA, and showed high concordance in genotypes between ctDNA and tumor tissue DNA for evaluating disease progression in melanoma patients. The novel microarray-based approach demonstrated high accuracy in monitoring disease progression of melanoma patients by detecting ctDNA BRAF mutations.
Review
Medicine, General & Internal
Nancy Huang, Katie J. Lee, Mitchell S. Stark
Summary: Melanoma is the leading cause of skin cancer deaths, and liquid biomarkers have advantages in monitoring tumor burden and heterogeneity. The only serological marker currently used, lactate dehydrogenase, is not specific or sensitive enough. This review summarizes the current research on liquid biomarkers, including circulating tumor cells, circulating tumor DNA, microRNA, and extracellular vesicles.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
M. A. Gouda, J. Polivka, H. J. Huang, I Treskova, K. Pivovarcikova, T. Fikrle, V Woznica, D. J. Dustin, S. G. Call, F. Meric-Bernstam, M. Pesta, F. Janku
Summary: This study used ultrasensitive ddPCR technology to detect ctDNA in pre- and post-surgical blood samples from patients with resectable melanoma. Patients with detected ctDNA in post-surgical samples had inferior treatment outcomes.
Article
Biochemistry & Molecular Biology
Yuka Tanaka, Maho Murata, Che-Hung Shen, Masutaka Furue, Takamichi Ito
Summary: The study found that high expression of NECTIN4 is associated with disease-free survival in melanoma, and in BRAFi-resistant melanoma cells, both NECTIN4 and the PI3K/Akt pathway are upregulated. Inhibiting NECTIN4 can increase the sensitivity of BRAFi-resistant cells to BRAFi, offering a novel treatment strategy for melanoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Yoshiaki Shoji, Matias A. Bustos, Rebecca Gross, Dave S. B. Hoon
Summary: In this article, we reviewed studies from the past 15 years on the assessment of circulating tumor cells (CTCs) in cutaneous melanoma patients in relation to different clinical outcomes. The most common method used was quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate multiple molecular melanoma-associated antigen (MAA) markers, which improved the sensitivity of the assay, addressed tumor heterogeneity, and predicted patient outcomes. Multicenter studies showed the utility of CTC assays in reducing bias observed in single-center trials. The recent development of CTC enrichment platforms provided reproducible methods for CTC assessment, enabling genomic profiling of both multiple mRNAs and DNAs. CTC assessment provided specific translational information on tumor progression, treatment response prediction, and survival outcomes for cutaneous melanoma patients.
Article
Oncology
Caroline Brenner Thomsen, Amanda Dandanell Juul, Anna Cecilie Lefevre, Christina Glismand Truelsen, Edina Dizdarevic, Heidi Ryssel, Ina Mathilde Kjaer, Karen Lycke Wind, Louise Bach Callesen, Louise Faaborg Larsen, Malene Stochkel Frank, Rikke Fredslund Andersen, Karen-Lise Garm Spindler, Anders Jakobsen
Summary: This commentary discusses the importance of standardizing circulating tumor DNA (ctDNA) analyses for monitoring metastatic solid tumors, aiming to improve its clinical validity.
Review
Oncology
Chiao-Ling Li, Shiou-Hwei Yeh, Pei-Jer Chen
Summary: Cell-free tumor DNA (ctDNA) is a promising tumor marker that can reflect tumor burden, behavior, and prognosis. However, there are still challenges to be addressed before ctDNA can be used as a tumor marker. We propose using exogenous viral DNA integration to generate virus-host chimera DNA (vh-DNA) as a potential new biomarker. vh-DNA may overcome detection problems and serve as a universal marker for monitoring tumor expansion or burden related to oncogenic viruses.
Article
Biochemistry & Molecular Biology
Woo Kyung Ryu, Sekyung Oh, Jun Hyeok Lim, Seung Jae Lee, Hyun-Tae Shin, Jeong-Seon Ryu
Summary: Recent research suggests that changes in ctDNA levels are correlated with TB changes, and the detection of ctDNA can be used to predict new metastases, rapid tumor growth, and poor survival in NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
Kaori Sakaizawa, Atsuko Ashida, Aya Uchiyama, Takamichi Ito, Yasuhiro Fujisawa, Dai Ogata, Shigeto Matsushita, Kazuyasu Fujii, Satoshi Fukushima, Yoshitsugu Shibayama, Naohito Hatta, Tatsuya Takenouchi, Jiro Uehara, Ryuhei Okuyama, Naoya Yamazaki, Hisashi Uhara
JOURNAL OF DERMATOLOGICAL SCIENCE
(2015)
Letter
Dermatology
Atsuko Ohashi, Akane Minagawa, Atsuko Ashida, Hiroshi Koga, Hisashi Uhara, Ryuhei Okuyama
JOURNAL OF DERMATOLOGY
(2015)
Article
Dermatology
Atsuko Ashida, Hisashi Uhara, Asuka Mikoshiba, Kaori Sakaizawa, Naomi Kumagai, Hiroshi Koga, Ryuhei Okuyama
ACTA DERMATO-VENEREOLOGICA
(2016)
Letter
Dermatology
Atsuko Ashida, Eisaku Ogawa, Hisashi Uhara, Tomonobu Koizumi, Ryuhei Okuyama
JOURNAL OF DERMATOLOGICAL SCIENCE
(2016)
Letter
Dermatology
Atsuko Ashida, Akira Shimizu, Ryuhei Okuyama
JOURNAL OF DERMATOLOGY
(2016)
Letter
Dermatology
Y. Kumagai, N. Umegaki-Arao, T. Sasaki, Y. Nakamura, H. Takahashi, A. Ashida, Y. Tsunemi, M. Kawashima, A. Shimizu, A. Ishiko, K. Nakamura, H. Tsuchihashi, M. Amagai, A. Kubo
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2017)
Article
Dermatology
Asuka Mikoshiba, Atsuko Ashida, Kaori Sakaizawa, Yukiko Kiniwa, Ryuhei Okuyama
JOURNAL OF DERMATOLOGICAL SCIENCE
(2020)
Letter
Dermatology
Takushi Shirai, Yukiko Kiniwa, Norito Ishii, Takashi Hashimoto, Yasushi Senoo, Kazuhisa Urushihata, Atsuko Ashida, Ryuhei Okuyama
JOURNAL OF DERMATOLOGY
(2020)
Article
Oncology
Yukiko Kiniwa, Kenta Nakamura, Asuka Mikoshiba, Atsuko Ashida, Yasuyuki Akiyama, Atsushi Morimoto, Ryuhei Okuyama
Summary: CTCs are present even in early-stage melanoma and the number of CTCs may reflect patients' responses to BRAF/MEK inhibitor treatment. Furthermore, genetic heterogeneity of BRAF may contribute to resistance to BRAF/MEK inhibitors.
Letter
Dermatology
Hirotaka Midorikawa, Yukiko Kiniwa, Akane Minagawa, Kana Osawa, Takushi Shirai, Tasuku Sano, Kenta Nakamura, Atsuko Ashida, Ken-ichi Ueno, Takuya Takeichi, Masashi Akiyama, Ryuhei Okuyama
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Atsuko Ashida, Shuta Tomida, Tokuro Iwabuchi, Yuki Sato, Yukiko Kiniwa, Ryuhei Okuyama
Summary: This study aimed to investigate the association between skin dysbiosis and skin rash induced by EGFRI. The results showed that the abundance of Cutibacterium acnes decreased while Staphylococcus aureus, Corynebacterium spp., Staphylococcus epidermidis, or Proteobacteria increased after EGFRI initiation. Skin pH increased and water capacitance decreased. The skin microbiome composition of patients with severe rash was significantly different from that of healthy controls. Moreover, skin dysbiosis did not return to baseline during long-term EGFRI treatment.
EXPERIMENTAL DERMATOLOGY
(2023)
Editorial Material
Dermatology
Kaori Sakaizawa, Atsuko Ashida, Yukiko Kiniwa, Ryuhei Okuyama
ACTA DERMATO-VENEREOLOGICA
(2020)
Article
Dermatology
Atsuko Ashida, Kaori Sakaizawa, Hisashi Uhara, Ryuhei Okuyama
ACTA DERMATO-VENEREOLOGICA
(2017)
Letter
Medical Laboratory Technology
Kaori Sakaizawa, Atsuko Ashida, Hisashi Uhara, Ryuhei Okuyama
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2017)